FORA Capital’s Neurocrine Biosciences NBIX Stock Holding History

FORA Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$908K	Buy	5,394 +1,237	+30%	+$184K	0.06%	223
2026 Q1	$548K	Buy	+4,157	New	+$552K	0.04%	299
2024 Q4	–	Sell	-16,752	Closed	-$1.93M	–	526
2024 Q3	$1.93M	Buy	+16,752	New	+$2.3M	0.23%	133
2023 Q3	–	Sell	-2,298	Closed	-$217K	–	542
2023 Q2	$217K	Sell	2,298 -7,367	-76%	-$720K	0.03%	316
2023 Q1	$978K	Buy	+9,665	New	+$1.01M	0.1%	249
2022 Q4	–	Sell	-8,272	Closed	-$879K	–	601
2022 Q3	$879K	Buy	+8,272	New	+$839K	0.17%	183
2021 Q3	–	Sell	-2,863	Closed	-$279K	–	684
2021 Q2	$279K	Sell	2,863 -258	-8%	-$24.7K	0.05%	367
2021 Q1	$304K	Buy	+3,121	New	+$327K	0.1%	227
2020 Q4	–	Sell	-2,204	Closed	-$212K	–	1060
2020 Q3	$212K	Sell	2,204 -3,341	-60%	-$386K	0.14%	166
2020 Q2	$676K	Buy	+5,545	New	+$613K	0.23%	118
2020 Q1	–	Sell	-8,281	Closed	-$890K	–	1226
2019 Q4	$890K	Buy	+8,281	New	+$867K	0.09%	274

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FORA Capital's NBIX Position: Q2 2026 in Review

FORA Capital increased its Neurocrine Biosciences (NBIX) stake by 30% in Q2 2026, buying an estimated $184K and bringing the position to 5,394 shares worth $908K. The position accounts for 0.06% of the portfolio, ranked #223.

FORA Capital first reported a position in NBIX in Q4 2019 and has held it in 11 quarters since. The position peaked at $1.93M in Q3 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

FORA Capital held 5,394 shares of Neurocrine Biosciences worth $908K as of Q2 2026.
FORA Capital bought 1,237 Neurocrine Biosciences shares in Q2 2026, an estimated $184K.
Neurocrine Biosciences made up 0.06% of FORA Capital's portfolio in Q2 2026, its #223 holding.
FORA Capital first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 11 quarters since.
FORA Capital's Neurocrine Biosciences position peaked at $1.93M in Q3 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.